key: cord-0918538-508rseat authors: Standl, Eberhard; Schnell, Oliver title: Heart failure outcomes and Covid-19 date: 2021-04-05 journal: Diabetes Res Clin Pract DOI: 10.1016/j.diabres.2021.108794 sha: fd998a79a9a0c811b68f6c32dfb6c3a8b31baf70 doc_id: 918538 cord_uid: 508rseat Pre-existing heart failure (HF) in diagnosed patients with coronavirus disease 2019 (COVID-19) is associated with a close to two-fold increased mortality rate compared to COVID-19 patients without prior HF history. Moreover, based both on biomarker as well as imaging findings, widespread endothelial and cardiac injury seems to be present in many patients presenting with COVID-19, associated with adverse outcomes including new onset HF. Systematic echocardiographic studies in patients with COVID-19 indicate that the most common cardiac pathology is right ventricular (RV) dilatation (39%) over and above both left ventricular (LV) diastolic dysfunction (16%) and LV systolic dysfunction (10%). In addition, myocardial injury, assessed by magnetic resonance imaging (MRI), is observed in some 55% to 70% of patients recently recovered from COVID-19 even in those who didn’t get very sick during the acute illness. These observations seem to indicate a potentially rather high risk of clinical HF emerging in patients post-COVID-19, warranting close long-term monitoring of patients during recovery. On the other hand, given the established adverse prognostic role that pre-existing HF plays as a comorbidity in the context of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, it not only seems important in the still ongoing COVID-19 pandemic that all patients with known HF should proactively be well controlled and treated according to current guidelines, but also additionally be considered for priority vaccination against the SARS-CoV-2 infection if not yet vaccinated. The unprecedented worldwide spread of severe and potentially life-threatening infections caused by the newly arisen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is still ongoing and has truly reached pandemic dimensions (1) (2) (3) (4) (5) (6) (7) (8) , posing new challenges to patients suffering from non-communicable diseases such as obesity, diabetes mellitus, hypertension, cardiovascular diseases and heart failure. In fact, these diseases, often associated with an unhealthy metabolism, when being present as preexisting co-morbidities in people developing coronavirus disease 2019 (COVID-19) may largely determine an adverse outcome including a high mortality rate (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) . The loss of lives related to COVID-19 seems to be enormous and an excess death toll of about 20% over and above the normally observed mortality rates in populations has been shown, e.g. in the United States (12) . Indeed COVID-19 has emerged as a leading cause of death during the pandemic in this country (13) . People not only died from the primary affection of the lungs, an extensive interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), but also due to acute cardiovascular events, ventricular fibrillation, heart failure, acute coagulopathies, thrombo-embolic disease, acute kidney and/or liver injury, and multi-organ failure (14) (15) (16) (17) . Besides infecting multiple organs such as the lungs and the heart, SARS-CoV-2 was found causing widespread endotheliitis by entering and infecting endothelial cells inducing massive injury to the vasculature (18) and further augmenting pre-existing organ damage. The present overview seeks to highlight the prognostic impact of concomitant heart failure (HF) on adverse COVID-19 outcomes as well as -vice versa -the potential for longterm cardiac damage and risk of developing HF in survivors of COVID-19. A number of retrospective observational studies as well as a meta-analysis and systematic review including some 20,000 patients have looked into the prognostic impact of prior HF in patients hospitalized with COVID-19 (9, 10, 19 Another report from Spain analyzed 3,080 consecutive patients with confirmed COVID-19 infection and at least 30-day follow-up, of whom 152 (4.9%) had a previous HF history (10) . The latter developed acute HF during hospitalisation significantly more often (11.2% vs 2.1%; p<0.001), had higher levels of NT-proBNP and showed higher mortality rates (48.7% vs 19.0%; p<0.001). Remarkably, also 60 patients without previous history of HF experienced acute HF during hospitalization for COVID-19 with a high mortality risk compared with those without acute HF (46.8% vs 19.7%; p<0.001). Finally, withdrawal of beta-blockers, mineralocorticoid antagonists and ACE/ARB inhibitors was associated with a significant increase of in-hospital mortality. These findings were largely consistent with results of a meta-analysis and systematic review based on 21,640 patients from 18 studies derived from a global literature search in PubMed, EuropePMC, SCOPUS, Cochrane Central Database, and medRxiv with the search terms, "Heart failure" and "COVID-19" (19) . HF was found to be significantly associated with need of hospitalization for COVID-19 (Table 1) . Moreover, HF was associated with adverse outcome of COVID-19 (defined by mortality or incidence of severe COVID-19 infection, admission to intensive care unit (ICU), and use of ventilator, Table 1 ). Finally, patients with pre-existing HF were associated with higher mortality. Particularly noteworthy was the highly increased incidence of new-onset HF in hospitalized patients with COVID-19 (see also Table 1 ). Along with the first publications on patients suffering from COVID-19, it soon became apparent that a wide array of biomarkers not only was abnormally elevated but also that this increase was associated with a more adverse clinical outcome with requirement of intensive care and mechanical ventilation etc., often heralding a fatal course (2, (6) (7) (8) (9) (10) (11) (20) (21) (22) (23) . These biomarkers signalled inflammatory activation, cytokine storm and distress, endothelial damage, thrombosis and hypercoagulation, but also bleeding, and not the least, myocardial injury. Biomarkers involved encompassed CRP, interleukin 1ß, interleukin 6, TNF-alpha, ferritin, procalcitonin, D-dimer, PAI-1, and prothrombin time, as well as troponin I, CK-MB, and natriuretic peptides (2, (6) (7) (8) (9) (10) (11) (20) (21) (22) (23) (24) (25) . Although biomarker abnormalities must not be confused with definitive diagnosis, they fit well with clinical observations made in patients with COVID-19. Those findings clearly indicated that patients developed signs and symptoms of myocardial infarction, myocarditis, stroke, deep venous thrombosis and subsequent pulmonary embolism, but also gastrointestinal or intracranial bleeding, all contributing to multi-organ disease and failure, and ultimately to fatal outcomes (14) (15) (16) (17) . Single case reports described the occurrence of acute myopericarditis with systolic dysfunction in otherwise healthy middle-aged people on admission for COVID-19, based on an increase in levels of NT-proBNP and high-sensitivity troponin T and confirmed by echocardiography changes and diffuse biventricular myocardial oedema and late gadolinium enhancement on cardiac magnetic resonance imaging (26, 27) . In a systematic echocardiographic study in patients with COVID-19 (28), the most common cardiac pathology was RV dilatation (39%) which was more common than both left ventricular (LV) diastolic dysfunction (16%) and LV systolic dysfunction (10%). In fact, it was concluded that LV systolic function may be preserved in these patients, although LV diastolic function and RV function are impaired (27) (28) (29) . Post mortem studies showed COVID-19 causing profound multisystem pathology (16, (30) (31) (32) . Both pulmonary and cardiovascular involvement were predominant pathological features. In the lung, the major histological feature exhibited diffuse alveolar damage with extensive hyaline membrane formation and oedema, alongside microthrombi in small pulmonary vessels. In the heart, massive inflammatory infiltrates with myocarditis, pericarditis, vasculitis, focal necrosis, and vascular fibrosis were seen. In fact, direct viral infection of endothelial cells and diffuse endothelial inflammation has been demonstrated in the heart, the lungs, the small bowels, and the kidneys (18) . Moreover, patients with COVID -19 requiring admission to intensive care units (ICU) had significantly higher circulating numbers of endothelial cells, i.e. stressed cells detached from injured vessels, than non-ICU patients and the extent of endothelial injury was correlated with putative markers of disease severity and inflammatory cytokines (33) . Together, these data provide in vivo evidence that endothelial injury is a key feature of COVID-19. This is also in line with impressive post mortem extra-cardio-pulmonary manifestations in deceased COVID-19 patients showing hepatic, kidney, splenic, and bone marrow involvement, as well as microvascular injury and thrombosis (16, (30) (31) (32) . Notably, the findings appear to be similar in patients with or without pre-existing medical comorbidities. Hence, SARS-CoV-2 infection can cause multisystem disease and significant pathology in most organs, including in the heart, regardless of comorbidities. The underlying widespread endotheliitis and T-cell related inflammation of cardiac tissue seem to be particularly important pathogenetic mechanisms, probably shedding some light on the high risk of incident heart failure occurring in patients hospitalized for COVID-19 (9, 26, 27, 29) and may allude to a potential long-term risk of developing heart failure in patients seemingly having recovered from a SARS-CoV-2 infection. Indeed, presence of myocardial injury assessed by MRI has been observed in a series of Regarding HF therapy, this also involves the appropriate use of ACE inhibitors or angiotensin receptor blockers (ARBs) (8) . Issues had been raised over the theoretical possibility that because SARS-CoV-2 utilizes ACE2 receptor to enter into host cells, particularly pneumocytes (40) , and because both ACE inhibitors and ARBs can increase ACE2 expression (41) , these drugs may potentially indirectly facilitate the penetration of the virus into the cells. These fears could convincingly be dismissed by a large number of studies showing not only the safety of both ACE inhibitor and ARB use in COVID-19 but also a potential benefit of these drugs (8) (9) (10) 42) . Also, the prompt positioning of several scientific societies and of the European Medicines Agency very clearly pointed out that no evidence was available to justify the stop of using these drugs, which have been demonstrated to save millions of lives (43) . So, continuation of the guideline-based use of ACE inhibitors and ARBs in all HF patients along with meticulously striving for best treatment and control of HF is an important clinical recommendation. A second clinical implication refers to the need of monitoring for emerging HF in all patients having recovered from COVID-19, even if the acute illness has not been severe. It should be acknowledged, however, that there might be some publication bias of more unusual single cases being reported, requiring further comprehensive and representative evaluation on what the true threat of developing HF is in mild cases, especially in young people suffering from the disease without almost any symptoms. Nevertheless, regular screening for signs and symptoms of HF seems advisable post COVID for the time being which should be provided by the responsible physician and diagnosis established in cooperation with the cardiologist, as also outlined in several manuscripts of this special issue on HF. ES and OS declare having no competing interests with respect to the research, authorship, and/or publication of this article. OS reports to be CEO of Sciarc GmbH, Germany. A novel coronavirus from patients with pneumonia in China China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany Covid-19 in South Korea -Challenges of Subclinical Manifestations COVID-19 infection in Italian People with diabetes: lessons learned for our future (an experience to be used) The characteristics of 50 hospitalized COVID-19 patients with and without ARDS Clinical characteristics of Covid-19 in New York City Issues of Cardiovascular Risk Management in People With Diabetes in the COVID-19 Era Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19 Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study Excess Deaths From COVID-19 and Other Causes COVID-19 as the Leading Cause of Death in the United States Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study Analysis of the clinical characteristics of 77 COVID-19 deaths. Sci Rep Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study Deaths From COVID-19 Endothelial cell infection and endotheliitis in COVID-19 Effect of heart failure on the outcome of COVID-19 -A meta analysis and systematic review Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19 Prognostic value of Cardiac Biomarkers in COVID-19 Infection: A Meta-analysis. Res Sq A meta-analysis of potential biomarkers associated with severity of coronavirus disease Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19 Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19) Researchers Investigate What COVID-19 Does to the Heart The spectrum of cardiac manifestations in coronavirus disease 2019 (COVID-19) -a systematic echocardiographic study The right ventricle in COVID-19 patients Autopsy findings in COVID-19-related deaths: a literature review Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Postmortem examination of patients with COVID-19 Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19 Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19) Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance Myocarditis and inflammatory cardiomyopathy: current evidence and future directions A patient with rapid worsening dyspnoea during Covid-19 pandemic COVID-19 and Heart Failure With Preserved Ejection Fraction ACC Health Policy Statement on Cardiovascular Disease Considerations for COVID-19 Vaccine Prioritization Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein COVID-19, diabetes mellitus and ACE2: the conundrum Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19 EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic The editorial support provided by Dr. Annique Dombrowsky is highly appreciated.The project has been supported by an educational grant of the Association for the Support of International Scientific Communication in Diabetology e.V., Munich, Germany.